Patents by Inventor Lingyin Li

Lingyin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240299532
    Abstract: Provided herein are vaccine delivery systems including a polymer hydrogel non-covalently crossed-linked with a plurality of nanoparticles, a dinucleotide adjuvant encapsulated in the hydrogel, and an antigen encapsulated in the hydrogel. The provided vaccine delivery systems are particularly useful for slowly releasing the antigen and adjuvant within a subject, thereby triggering a more therapeutically effective immune response. Also provided are kits including the disclosed vaccine delivery systems, and methods of using the disclosed materials.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 12, 2024
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Eric Andrew Appel, Emily C. Gale, Lingyin Li, Lauren J. Lahey
  • Publication number: 20230277570
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
    Type: Application
    Filed: May 16, 2023
    Publication date: September 7, 2023
    Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
  • Patent number: 11707471
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: July 25, 2023
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
  • Patent number: 11701371
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 18, 2023
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
  • Publication number: 20230190927
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a cell impermeable ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP 1. Also provided are vaccine compositions and methods relate thereto. Aspects of the methods include administering to a subject an effective amount of a cell impermeable ENPP1 inhibitor to inhibit the hydrolysis of cGAMP in combination with a vaccine.
    Type: Application
    Filed: May 4, 2021
    Publication date: June 22, 2023
    Inventors: Lingyin Li, Randolph Mellus Johnson
  • Publication number: 20230103498
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 6, 2023
    Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
  • Publication number: 20220289775
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.
    Type: Application
    Filed: January 30, 2020
    Publication date: September 15, 2022
    Inventors: Lingyin LI, Mark Smith, Jacqueline Ann CAROZZA, Volker BOEHNERT
  • Publication number: 20210369747
    Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.
    Type: Application
    Filed: September 7, 2018
    Publication date: December 2, 2021
    Inventors: Lingyin LI, Mark SMITH, Kelsey Erin SHAW, Jacqueline Ann CAROZZA, Volker BOEHNERT
  • Patent number: 9006394
    Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: April 14, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura Lee Kiessling, Joseph R. Klim, Lingyin Li
  • Publication number: 20140287505
    Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.
    Type: Application
    Filed: January 23, 2014
    Publication date: September 25, 2014
    Inventors: Laura Lee Kiessling, Joseph R. Klim, Lingyin Li
  • Patent number: 8648170
    Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: February 11, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Laura Lee Kiessling, Joseph Robert Klim, Lingyin Li
  • Publication number: 20100087004
    Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.
    Type: Application
    Filed: September 18, 2009
    Publication date: April 8, 2010
    Inventors: Laura Lee Kiessling, Joseph Robert Klim, Lingyin Li